CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

CVRx, Inc. (NASDAQ: CVRX), a pioneering medical device company specializing in neuromodulation solutions for cardiovascular diseases, is set to participate in the Piper Sandler 37th Annual Healthcare Conference. The event will take place on Wednesday, December 3, 2025, with CVRx's management team scheduled to engage in a fireside chat at 2:00 p.m. (ET). Interested parties can access a live audio webcast through the investor relations section of CVRx's website.

CVRx is known for its innovative approach to treating heart-related conditions, with its flagship product, Barostim™, being the first FDA-approved medical technology that utilizes neuromodulation to alleviate symptoms in heart failure patients. Barostim is an implantable device that utilizes electrical pulses to stimulate baroreceptors in the carotid artery, aiming to rebalance the autonomic nervous system and mitigate heart failure symptoms. The technology has earned the FDA's Breakthrough Device designation and is FDA-approved for heart failure treatment in the United States. Additionally, Barostim holds CE Mark approval for both heart failure and resistant hypertension within the European Economic Area, demonstrating its compliance with EU Medical Device Regulations.

With a strong foothold in the market, CVRx is committed to advancing cardiovascular care through its groundbreaking therapies. The company's participation in the Piper Sandler conference highlights its ongoing commitment to investor engagement and transparency about its innovative solutions. For more information on Barostim and CVRx's endeavors, stakeholders can visit the company's official website.

For media inquiries, Mark Klausner or Mike Vallie at ICR Healthcare can be contacted at 443-213-0501 or via email at ir@cvrx.com. Emily Meyers of CVRx can also be reached at 763-416-2853 for further information.

As CVRx, Inc. (NASDAQ: CVRX) prepares to participate in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, this event presents a pivotal moment for investors to reassess the company's position within the burgeoning medical device market, particularly in the cardiovascular space. The company's flagship product, Barostim™, which received FDA Breakthrough Device designation, stands out as a groundbreaking solution for heart failure patients, offering the potential for long-term growth given the increasing prevalence of cardiovascular diseases.

The upcoming fireside chat, scheduled for 2:00 p.m. ET, provides an excellent opportunity for investors to gain insights directly from the management team, including updates on Barostim's market performance, potential partnerships, and future innovations in neuromodulation technology. Given that cardiovascular diseases remain one of the leading causes of morbidity and mortality globally, the demand for effective therapeutic solutions is likely to grow, presenting a favorable market environment for CVRx.

Investors should consider the implications of regulatory approvals and market penetration in both the U.S. and European markets, where Barostim has secured CE Mark approval. The ability of CVRx to expand its footprint internationally could significantly affect revenue projections and investor confidence moving forward.

Additionally, the healthcare conference serves as a platform for CVRx to potentially attract new institutional interest and analyze market sentiments towards their pioneering approach. Given the historical performance and innovative strengths of CVRx, investors might view this participation as a strategic move to solidify its standing and foster further engagement with stakeholders.

In conclusion, CVRx continues to showcase its commitment to addressing critical healthcare needs, and attentive investors should monitor this event for significant developments that can influence stock performance in the coming months.